TAFRO syndrome

from Wikipedia, the free encyclopedia
Classification according to ICD-10
M35.8 Other specified diseases with systemic involvement of the connective tissue
ICD-10 online (WHO version 2019)

The Tafro syndrome acronym for T hrombozytopenie , A Nazarka , F ieber , R etikuläre fibrosis and O rganomegalie , is a very rare congenital disease with the eponymous main features.

The syndrome is considered a variant of the idiopathic multicenter form of Castleman's disease (iMCD).

Synonyms are: thrombocytopenia-anasarca-fever-adrenal insufficiency-organomegaly syndrome; English Castleman-Kojima disease

The name refers to the Japanese pathologist Masaru Kojima and colleagues.

The frequency is given as less than 1 in 1,000,000. The disease can occur at any age.

For more information on the clinic, diagnostics and treatment see p. with Castleman's disease .

literature

  • T. Igawa, Y. Sato: TAFRO Syndromes. In: Hematology / oncology clinics of North America. Volume 32, number 1, 02 2018, pp. 107-118, doi: 10.1016 / j.hoc.2017.09.009 , PMID 29157612 (review).
  • N. Iwaki, DC Fajgenbaum, CS Nabel, Y. Gion, E. Kondo, M. Kawano, T. Masunari, I. Yoshida, H. Moro, K. Nikkuni, K. Takai, K. Matsue, M. Kurosawa, M. Hagihara, A. Saito, M. Okamoto, K. Yokota, S. Hiraiwa, N. Nakamura, S. Nakao, T. Yoshino, Y. Sato: Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8- negative multicentric Castleman's disease. In: American Journal of Hematology . Volume 91, Number 2, February 2016, pp. 220-226, doi: 10.1002 / ajh.24242 , PMID 26805758 .
  • Y. Masaki, H. Kawabata, et al. a .: Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. In: International Journal of Hematology. 103, 2016, p. 686.
  • H. Kawabata, K. Takai, M. Kojima, N. Nakamura, S. Aoki, S. Nakamura, T. Kinoshita, Y. Masaki: Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (June 6, 2012) and Nagoya meetings (September 22, 2012). In: Journal of clinical and experimental hematopathology: JCEH. Volume 53, Number 1, 2013, pp. 57-61, PMID 23801135 .
  • Y. Masaki, A. Nakajima, H. Iwao, N. Kurose, T. Sato, T. Nakamura, M. Miki, T. Sakai, T. Kawanami, T. Sawaki, Y. Fujita, M. Tanaka, T. Fukushima, T. Okazaki, H. Umehara: Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia – a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? In: Journal of clinical and experimental hematopathology: JCEH. Volume 53, Number 1, 2013, pp. 79-85, PMID 23801138 .

Individual evidence

  1. ↑ a b TAFRO syndrome. In: Orphanet (Rare Disease Database).
  2. ↑ K. Sakashita, K. Murata, M. Takamori: TAFRO syndrome: current perspectives. In: Journal of blood medicine. Volume 9, 2018, pp. 15-23, doi: 10.2147 / JBM.S127822 , PMID 29403325 , PMC 5784582 (free full text) (review).
  3. ↑ JM Hawkins, V. Pillai: TAFRO syndrome or Castleman-Kojima syndrome: a variant of multicentric Castleman disease. In: Blood. 126, 2015, p. 2163, doi: 10.1182 / blood-2015-07-662122
  4. ↑ M. Kojima, S. Nakamura, M. Nishikawa, H. Itoh, S. Miyawaki, N. Masawa: Idiopathic multicentric Castleman's disease. A clinicopathologic and immunohistochemical study of five cases. In: Pathology, research and practice. Volume 201, number 4, 2005, pp. 325-332, doi: 10.1016 / j.prp.2005.01.006 , PMID 15991840 .